
Skyhawk Reports Positive Phase 1/2 Results for Huntington’s Drug SKY-0515
Patients with Huntington’s disease treated with Skyhawk Therapeutics’ oral drug SKY-0515 showed no clinical worsening after twelve months, according to interim data from a Phase 1/2 trial. The findings, presented at the European Academy of Neurology, suggest the small molecule therapy may stabilize disease progression in early-stage participants.

























